1. Liver enzyme CYP2D6 gene and tardive dyskinesia.
- Author
-
Lu JY, Tiwari AK, Freeman N, Zai GC, Luca V, Müller DJ, Tampakeras M, Herbert D, Emmerson H, Cheema SY, King N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, and Zai CC
- Subjects
- Adult, Antipsychotic Agents metabolism, Antipsychotic Agents pharmacology, Cytochrome P-450 CYP2D6 metabolism, Female, Humans, Liver drug effects, Male, Middle Aged, Schizophrenia drug therapy, Schizophrenia enzymology, Tardive Dyskinesia enzymology, Tardive Dyskinesia epidemiology, Cytochrome P-450 CYP2D6 genetics, Liver metabolism, Schizophrenia genetics, Tardive Dyskinesia genetics, White People genetics
- Abstract
Background: Tardive dyskinesia (TD) is an iatrogenic involuntary movement disorder occurring after extended antipsychotic use with unclear pathogenesis. CYP2D6 is a liver enzyme involved in antipsychotic metabolism and a well-studied gene candidate for TD. Materials & methods: We tested predicted CYP2D6 metabolizer phenotype with TD occurrence and severity in our two samples of European chronic schizophrenia patients (total n = 198, of which 82 had TD). Results: TD occurrence were associated with extreme metabolizer phenotype, controlling for age and sex (p = 0.012). In other words, individuals with either increased and no CYP2D6 activity were at higher risk of having TD. Conclusion: Unlike most previous findings, TD occurrence may be associated with both extremes of CYP2D6 metabolic activity rather than solely for poor metabolizers.
- Published
- 2020
- Full Text
- View/download PDF